Search Results - "GIANGRANDE, P. L. F."

European principles of inhibitor management in patients with haemophilia by Giangrande, P L F, Hermans, C, O'Mahony, B, de Kleijn, P, Bedford, M, Batorova, A, Blatný, J, Jansone, K

“…In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of…”
Get full text

European principles of inhibitor management in patients with haemophilia: implications of new treatment options by Hermans, C, Giangrande, P. L. F, O'Mahony, B, de Kleijn, P, Bedford, M, Batorova, A, Blatný, J, Jansone, K, Astermark, J, Crato, M, d'Oiron, R, Dougall, A, Fijnvandraat, K, Granhaug, S, Jiménez-Yuste, V, JokiÄ, M, Lobet, S, Nolan, B, Peyvandi, F, Ryan, A

“…Keywords: Haemophilia, Guidelines, Inhibitors, Factor VIII, Factor IX, Bypassing agents, Emicizumab, Immune tolerance…”
Get full text

Haemophilia care in Europe - a survey of 35 countries by O'Mahony, B., Noone, D., Giangrande, P. L. F., Prihodova, L.

“…Summary A questionnaire was circulated in 2012 to national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC)…”
Get full text

Porcine factor VIII by GIANGRANDE, P. L. F.

Get full text

Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates by Giangrande, P. L. F., Peyvandi, F., O'Mahony, B., Behr‐Gross, M.‐E., Hilger, A., Schramm, W., Mannucci, P. M.

“…Introduction This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during…”
Get full text

Haemophilia Care in Europe: the ESCHQoL study by Schramm, W., Gringeri, A., Ljung, R., Berger, K., Crispin, A., Bullinger, M., Giangrande, P. L. F., Von Mackensen, S., Mantovani, L. G., Nemes, L., Serban, M.

“…Summary The aim of this study was to determine the clinical conditions of patients with haemophilia within Europe as recommended by the European Commission. In…”
Get full text

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 by Darby, S. C., Keeling, D. M., Spooner, R. J. D., Wan Kan, S., Giangrande, P. L. F., Collins, P. W., Hill, F. G. H., Hay, C. R. M.

“…Background: Previous studies of the development of inhibitors and their impact on mortality have been small. Objectives: To examine the development of…”
Get full text

Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors by GIANGRANDE, P. L. F., WILDE, J. T., MADAN, B., LUDLAM, C. A., TUDDENHAM, E. G. D., GODDARD, N. J., DOLAN, G., INGERSLEV, J.

“…Patients with haemophilia complicated by inhibitors have a significant burden of joint disease, which is associated with a negative impact on their quality of…”
Get full text

Haemophilia care in Europe: a survey of 19 countries by O'MAHONY, B., NOONE, D., GIANGRANDE, P. L. F., PRIHODOVA, L.

“…In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and…”
Get full text

Treatment of patients with haemophilia and inhibitory antibodies by GIANGRANDE, P. L. F

“…The development of inhibitory antibodies is a complication which arise in approximately 10% of patients with haemophilia A. The underlying genetic mutation is…”
Get full text

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A by Villar, A., Aronis, S., Morfini, M., Santagostino, E., Auerswald, G., Thomsen, H. F., Erhardtsen, E., Giangrande, P. L. F.

“…To establish the pharmacokinetic profile of activated recombinant coagulation factor VII (rFVIIa; NovoSeven®) in children with haemophilia A, and to compare it…”
Get full text

Consensus perspectives on prophylactic therapy for haemophilia: summary statement by Berntorp, E., Astermark, J., Björkman, S., Blanchette, V. S., Fischer, K., Giangrande, P. L. F., Gringeri, A., Ljung, R. C., Manco-Johnson, M. J., Morfini, M., Kilcoyne, R. F., Petrini, P., Rodriguez-Merchan, E. C., Schramm, W., Shapiro, A., M. Van Den Berg, H., Hart, C.

“…Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the…”
Get full text

Management of difficult-to-treat inhibitor patients by GIANGRANDE, P. L. F., ESCOBAR, M. A.

“…The workshop looked at seven scenarios based on fictional and real‐life cases of difficult‐to‐treat patients with haemophilia A or haemophilia B and inhibitors…”
Get full text

Gene therapy for hemophilia? No by Giangrande, P. L. F.

Get full text

Fondaparinux (Arixtra): a new anticoagulant by Giangrande, P L F

“…Fondaparinux is a promising new antithrombotic agent. This pentasaccharide selectively and specifically inhibits coagulation factor Xa, and requires…”
Get more information

Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs) by Giangrande, P. L. F.

“…Safety and efficacy of KOGENATE® Bayer (Kogenate® FS), a second‐generation full‐length recombinant factor VIII formulated with sucrose as stabilizer and…”
Get full text

Treatment of hemophilia: recombinant factors only? Yes by Giangrande, P. L. F.

Get full text

Adverse events in the prophylaxis of haemophilia by Giangrande, P. L. F.

“…Whilst prophylaxis undoubtedly offers many advantages, the potential for adverse effects must also be borne in mind. Modern plasma‐derived products have an…”
Get full text

Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction by CURRY, N. S., MISBAH, S. A., GIANGRANDE, P. L. F., KEELING, D. M.

“…We describe a young boy with severe haemophilia B who developed inhibitory antibodies and an anaphylactoid reaction to factor IX. Immune tolerance was achieved…”
Get full text

Choice of replacement therapy for hemophilia—a rebuttal by Giangrande, P. L. F.

Get full text